Drug Overview
Dacomitinib is a small-molecule, irreversible inhibitor of HER1, HER2, and HER4, under development by Pfizer. Mutation or amplification of the HER gene is seen in several malignancies including lung, breast, gastric, head and neck, and colorectal cancers. This rise in HER levels disrupts normal cell control mechanisms, promoting the formation of aggressive tumor cells. Dacomitinib blocks the signaling in both wild-type and mutant epidermal growth factor receptor NSCLC, including forms which are resistant to reversible HER inhibitors.
Dacomitinib is a small-molecule, irreversible inhibitor of HER1, HER2, and HER4, under development by Pfizer. Mutation or amplification of the HER gene is seen in several malignancies including lung, breast, gastric, head and neck, and colorectal cancers. This rise in HER levels disrupts normal cell control mechanisms, promoting the formation of aggressive tumor cells. Dacomitinib blocks the signaling in both wild-type and mutant epidermal growth factor receptor NSCLC, including forms which are resistant to reversible HER inhibitors.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
